Major Global Animal Health Company Launches 42-Day Confirmatory Study with ZIVO Bioscience’s Coccidiosis Treatment in Broiler Chickens
08 July 2024 - 10:00PM
Business Wire
ZIVO Bioscience, Inc. (NASDAQ: ZIVO), a pioneering
biotech/agtech R&D company dedicated to developing therapeutic,
medicinal and nutritional product candidates derived from
proprietary algal cultures, announces the initiation of a 42-day
confirmatory study targeting coccidiosis in collaboration with a
major global animal health company.
This new study aims to further validate the efficacy of ZIVO’s
non-antibiotic, immune-modulating product designed for the
prevention and treatment of coccidiosis in broiler chickens.
Building upon the positive outcomes of previous trials, this study
replicates real-world conditions to ensure the product's
effectiveness in commercial poultry production environments.
“We are delighted to support a global leader in animal health as
they perform this confirmatory study, which holds potential to
accelerate commercialization of our innovative treatment.
Coccidiosis costs the poultry industry more than $10 billion
annually, and traditional treatments rely heavily on antibiotics
and ionophores that have not seen significant innovation in over
six decades,” said John Payne, Chairman and CEO of ZIVO
Bioscience.
“This 42-day study is a significant step forward in our mission
to provide sustainable, antibiotic-free solutions for the poultry
industry. Our product represents a groundbreaking alternative
designed to boost the immune response of broiler chickens without
the adverse effects associated with legacy treatments. We are
optimistic the results of this study will further support its
market readiness,” he added.
Funded by the major animal health company, the study focuses on
the overall health and productivity of the birds under typical
industry conditions, and compares administration of ZIVO’s product
versus an ionophore-based treatment and versus an ionophore-based
treatment combined with ZIVO’s product. The study also compares the
benefits of ZIVO’s product combined with coccidiosis vaccine versus
administration without the vaccine. Results from the study are
expected to be available in September.
About Coccidiosis
Coccidiosis is a protozoal disease that causes diarrhea, weight
loss, decreased performance and increased mortality in poultry.
This disease represents a significant economic challenge for the
global poultry industry, as indicated by a 2020 study that
estimated annual costs ranging from $10 billion to $17 billioni.
Products for treating coccidiosis are mostly antibiotic- or
ionophore-based, and no significant new commercial technology has
been introduced in the past 60 years. The global poultry industry
spends more than $1.5 billion annually on coccidiosis control,
primarily using decades-old compounds that industry and consumers
alike want to replace due to the risks of developing drug
resistance. Coccidiosis is a common disease for chickens,
especially among young chicks, and can be fatal or result in
compromised digestion.
About ZIVO Bioscience
ZIVO Bioscience is a research and development company with an
intellectual property portfolio comprised of proprietary algal and
bacterial strains, biologically active molecules and complexes,
production techniques, cultivation techniques and patented or
patent pending inventions for applications in human and animal
health. Please visit www.zivobioscience.com for more
information.
Forward Looking Statements
Except for any historical information, the matters discussed in
this press release contain forward-looking statements within the
meaning of Section 27A of the Securities Act of 1933 and Section
21E of the Securities Exchange Act of 1934, including with respect
to the Company’s product candidate’s potential to generate revenues
and the expected time frame for results of future studies. Words
such as "expects," "anticipates," "intends," "plans," "believes,"
"seeks," "estimates" and similar expressions or variations of such
words are intended to identify forward-looking statements. Although
ZIVO believes that we have a reasonable basis for each
forward-looking statement, we caution you that these statements are
based on a combination of facts and factors currently known by us
and our expectations of the future, about which we cannot be
certain. Our actual future results may be materially different from
what we expect due to factors largely outside our control,
including risks that our strategic partnerships may not facilitate
the commercialization or market acceptance of our products; risks
that we will be unable to increase production sufficient to meet
our expected demand; risks that our products may not be ready for
commercialization in a timely manner or at all; risks that our
products will not perform as expected based on results of our
pre-clinical and clinical trials; our ability to raise additional
funds; uncertainties inherent in the development process of our
products; changes in regulatory requirements or decisions of
regulatory authorities; the size and growth potential of the
markets for our products; the results of clinical trials, our
ability to protect our intellectual property rights and other
risks, uncertainties and assumptions, including those described
under the heading “Risk Factors” in our filings with the Securities
and Exchange Commission. These forward–looking statements speak
only as of the date of this press release and ZIVO undertakes no
obligation to revise or update any forward–looking statements for
any reason, even if new information becomes available in the
future.
i Blake, D.P., Knox, J., Dehaeck, B. et al. Re-calculating the
cost of coccidiosis in chickens. Vet Res 51, 115 (2020).
https://doi.org/10.1186/s13567-020-00837-2
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240708605170/en/
ZIVO Bioscience Keith Marchiando, Chief Financial Officer
(248) 452-9866 x130 kmarchiando@zivobioscience.com
LHA Investor Relations Tirth T. Patel (212) 201-6614
tpatel@lhai.com
Zivo Bioscience (NASDAQ:ZIVO)
Historical Stock Chart
From Jun 2024 to Jul 2024
Zivo Bioscience (NASDAQ:ZIVO)
Historical Stock Chart
From Jul 2023 to Jul 2024